Seeking to rectify existing federal and state policies which prevent people with intellectual disabilities from accessing new therapies for Alzheimer’s disease, a group of international experts are calling for modification of “prior authorization” criteria to address inequitable access to anti-amyloid drugs for people with Down syndrome (DS).